Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
Apolipoprotein M.

Lipids in health and disease

Luo G, Zhang X, Nilsson-Ehle P, Xu N.
PMID: 15461812
Lipids Health Dis. 2004 Oct 04;3:21. doi: 10.1186/1476-511X-3-21.

Apolipoprotein M (apoM) is a 26-kDa protein that is mainly associated with high-density lipoprotein (HDL) in human plasma, with a small proportion present in triglyceride-rich lipoproteins (TGRLP) and low-density lipoproteins (LDL). Human apoM gene is located in p21.31 on...

Cite
Luo G, Zhang X, Nilsson-Ehle P, et al. Apolipoprotein M. Lipids Health Dis. 2004;3:21doi: 10.1186/1476-511X-3-21.
Luo, G., Zhang, X., Nilsson-Ehle, P., & Xu, N. (2004). Apolipoprotein M. Lipids in health and disease, 321. https://doi.org/10.1186/1476-511X-3-21
Luo, Guanghua, et al. "Apolipoprotein M." Lipids in health and disease vol. 3 (2004): 21. doi: https://doi.org/10.1186/1476-511X-3-21
Luo G, Zhang X, Nilsson-Ehle P, Xu N. Apolipoprotein M. Lipids Health Dis. 2004 Oct 04;3:21. doi: 10.1186/1476-511X-3-21. PMID: 15461812; PMCID: PMC523857.
Copy Download .nbib Format: NLM
Anaemia and other haematological abnormalities in patients admitted to long-term care.

Archives of gerontology and geriatrics

Granérus AK, Nilsson-Ehle H, Westin J.
PMID: 15374390
Arch Gerontol Geriatr. 1992 May-Jun;14(3):263-72. doi: 10.1016/0167-4943(92)90026-z.

We investigated the occurence and causes of anaemia and other haematological abnormalities in 142 elderly patients (43 men, 99 women; median age 79 and 80 years), admitted to long-term care. Healthy 81-year-old subjects (n = 220) were used as...

Cite
Granérus AK, Nilsson-Ehle H, Westin J. Anaemia and other haematological abnormalities in patients admitted to long-term care. Arch Gerontol Geriatr. 1992;14(3):263-72doi: 10.1016/0167-4943(92)90026-z.
Granérus, A. K., Nilsson-Ehle, H., & Westin, J. (1992). Anaemia and other haematological abnormalities in patients admitted to long-term care. Archives of gerontology and geriatrics, 14(3), 263-72. https://doi.org/10.1016/0167-4943(92)90026-z
Granérus, A K, et al. "Anaemia and other haematological abnormalities in patients admitted to long-term care." Archives of gerontology and geriatrics vol. 14,3 (1992): 263-72. doi: https://doi.org/10.1016/0167-4943(92)90026-z
Granérus AK, Nilsson-Ehle H, Westin J. Anaemia and other haematological abnormalities in patients admitted to long-term care. Arch Gerontol Geriatr. 1992 May-Jun;14(3):263-72. doi: 10.1016/0167-4943(92)90026-z. PMID: 15374390.
Copy Download .nbib Format: NLM
Determination of single-nucleotide polymorphism in the proximal promoter region of apolipoprotein M gene in coronary artery diseases.

International journal of general medicine

Zheng L, Luo G, Zhang X, Zhang J, Zhu J, Wei J, Mu Q, Chen L, Nilsson-Ehle P, Xu N.
PMID: 20360902
Int J Gen Med. 2009 Dec 29;2:177-82. doi: 10.2147/ijgm.s4687.

OBJECTIVE: It has been reported that single-nucleotide polymorphism (SNP) in the proximal promoter region of apolipoprotein M (apoM) gene may confer the risk in the development of type 2 diabetes (T2D) and coronary artery disease (CAD) in the Han...

Cite
Zheng L, Luo G, Zhang X, et al. Determination of single-nucleotide polymorphism in the proximal promoter region of apolipoprotein M gene in coronary artery diseases. Int J Gen Med. 2009;2:177-82doi: 10.2147/ijgm.s4687.
Zheng, L., Luo, G., Zhang, X., Zhang, J., Zhu, J., Wei, J., Mu, Q., Chen, L., Nilsson-Ehle, P., & Xu, N. (2009). Determination of single-nucleotide polymorphism in the proximal promoter region of apolipoprotein M gene in coronary artery diseases. International journal of general medicine, 2177-82. https://doi.org/10.2147/ijgm.s4687
Zheng, Lu, et al. "Determination of single-nucleotide polymorphism in the proximal promoter region of apolipoprotein M gene in coronary artery diseases." International journal of general medicine vol. 2 (2009): 177-82. doi: https://doi.org/10.2147/ijgm.s4687
Zheng L, Luo G, Zhang X, Zhang J, Zhu J, Wei J, Mu Q, Chen L, Nilsson-Ehle P, Xu N. Determination of single-nucleotide polymorphism in the proximal promoter region of apolipoprotein M gene in coronary artery diseases. Int J Gen Med. 2009 Dec 29;2:177-82. doi: 10.2147/ijgm.s4687. PMID: 20360902; PMCID: PMC2840562.
Copy Download .nbib Format: NLM
SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients.

International journal of proteomics

Rüetschi U, Stenson M, Hasselblom S, Nilsson-Ehle H, Hansson U, Fagman H, Andersson PO.
PMID: 26060582
Int J Proteomics. 2015;2015:841769. doi: 10.1155/2015/841769. Epub 2015 Apr 28.

Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma, is a heterogeneous disease where the outcome for patients with early relapse or refractory disease is very poor, even in the era of immunochemotherapy. In order to describe possible differences...

Cite
Rüetschi U, Stenson M, Hasselblom S, et al. SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients. Int J Proteomics. 2015;2015:841769doi: 10.1155/2015/841769.
Rüetschi, U., Stenson, M., Hasselblom, S., Nilsson-Ehle, H., Hansson, U., Fagman, H., & Andersson, P. O. (2015). SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients. International journal of proteomics, 2015841769. https://doi.org/10.1155/2015/841769
Rüetschi, Ulla, et al. "SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients." International journal of proteomics vol. 2015 (2015): 841769. doi: https://doi.org/10.1155/2015/841769
Rüetschi U, Stenson M, Hasselblom S, Nilsson-Ehle H, Hansson U, Fagman H, Andersson PO. SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients. Int J Proteomics. 2015;2015:841769. doi: 10.1155/2015/841769. Epub 2015 Apr 28. PMID: 26060582; PMCID: PMC4427854.
Copy Download .nbib Format: NLM
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.

Haematologica

Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sökler M, Dünzinger U, Nielsen T, Launonen A, Hiddemann W.
PMID: 32358081
Haematologica. 2020 May;105(5):1465. doi: 10.3324/haematol.2020.246991.

No abstract available.

Cite
Seymour JF, Marcus R, Davies A, et al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2020;105(5):1465doi: 10.3324/haematol.2020.246991.
Seymour, J. F., Marcus, R., Davies, A., Gallop-Evans, E., Grigg, A., Haynes, A., Herold, M., Illmer, T., Nilsson-Ehle, H., Sökler, M., Dünzinger, U., Nielsen, T., Launonen, A., & Hiddemann, W. (2020). Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica, 105(5), 1465. https://doi.org/10.3324/haematol.2020.246991
Seymour, John F, et al. "Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression." Haematologica vol. 105,5 (2020): 1465. doi: https://doi.org/10.3324/haematol.2020.246991
Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sökler M, Dünzinger U, Nielsen T, Launonen A, Hiddemann W. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2020 May;105(5):1465. doi: 10.3324/haematol.2020.246991. PMID: 32358081; PMCID: PMC7193496.
Copy Download .nbib Format: NLM
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.

Haematologica

Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sökler M, Dünzinger U, Nielsen T, Launonen A, Hiddemann W.
PMID: 30573503
Haematologica. 2019 Jun;104(6):1202-1208. doi: 10.3324/haematol.2018.209015. Epub 2018 Dec 20.

We evaluated early disease progression and its impact on overall survival (OS) in previously untreated follicular lymphoma patients in GALLIUM (

Cite
Seymour JF, Marcus R, Davies A, et al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2018;104(6):1202-1208doi: 10.3324/haematol.2018.209015.
Seymour, J. F., Marcus, R., Davies, A., Gallop-Evans, E., Grigg, A., Haynes, A., Herold, M., Illmer, T., Nilsson-Ehle, H., Sökler, M., Dünzinger, U., Nielsen, T., Launonen, A., & Hiddemann, W. (2019). Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica, 104(6), 1202-1208. https://doi.org/10.3324/haematol.2018.209015
Seymour, John F, et al. "Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression." Haematologica vol. 104,6 (2019): 1202-1208. doi: https://doi.org/10.3324/haematol.2018.209015
Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sökler M, Dünzinger U, Nielsen T, Launonen A, Hiddemann W. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2019 Jun;104(6):1202-1208. doi: 10.3324/haematol.2018.209015. Epub 2018 Dec 20. PMID: 30573503; PMCID: PMC6545851.
Copy Download .nbib Format: NLM
Iohexol Clearance for the Determination of Glomerular Filtration Rate: 15 Years' Experience in Clinical Practice.

EJIFCC

Nilsson-Ehle P.
PMID: 30429722
EJIFCC. 2001 Jul 22;13(2):48-52. eCollection 2001 Jul.

No abstract available.

Cite
Nilsson-Ehle P. Iohexol Clearance for the Determination of Glomerular Filtration Rate: 15 Years' Experience in Clinical Practice. EJIFCC. 2001;13(2):48-52
Nilsson-Ehle, P. (2001). Iohexol Clearance for the Determination of Glomerular Filtration Rate: 15 Years' Experience in Clinical Practice. EJIFCC, 13(2), 48-52.
Nilsson-Ehle, Peter. "Iohexol Clearance for the Determination of Glomerular Filtration Rate: 15 Years' Experience in Clinical Practice." EJIFCC vol. 13,2 (2001): 48-52.
Nilsson-Ehle P. Iohexol Clearance for the Determination of Glomerular Filtration Rate: 15 Years' Experience in Clinical Practice. EJIFCC. 2001 Jul 22;13(2):48-52. eCollection 2001 Jul. PMID: 30429722; PMCID: PMC6232857.
Copy Download .nbib Format: NLM
Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3.

HemaSphere

Eskelund CW, Dimopoulos K, Kolstad A, Glimelius I, Räty R, Gjerdrum LMR, Sonnevi K, Josefsson P, Nilsson-Ehle H, Bentzen HHN, Fagerli UM, Kuittinen O, Haaber J, Niemann CU, Pedersen LB, Larsen MT, Geisler CH, Hutchings M, Jerkeman M, Grønbæk K.
PMID: 33364550
Hemasphere. 2020 Dec 21;5(1):e510. doi: 10.1097/HS9.0000000000000510. eCollection 2021 Jan.

Mantle cell lymphoma (MCL) is an incurable disease with a highly variable clinical course. The prognosis after relapse is generally poor, and no standard of care exists. We investigated the postrelapse outcomes of 149 patients who were initially treated...

Cite
Eskelund CW, Dimopoulos K, Kolstad A, et al. Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3. Hemasphere. 2020;5(1):e510doi: 10.1097/HS9.0000000000000510.
Eskelund, C. W., Dimopoulos, K., Kolstad, A., Glimelius, I., Räty, R., Gjerdrum, L. M. R., Sonnevi, K., Josefsson, P., Nilsson-Ehle, H., Bentzen, H. H. N., Fagerli, U. M., Kuittinen, O., Haaber, J., Niemann, C. U., Pedersen, L. B., Larsen, M. T., Geisler, C. H., Hutchings, M., Jerkeman, M., & Grønbæk, K. (2021). Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3. HemaSphere, 5(1), e510. https://doi.org/10.1097/HS9.0000000000000510
Eskelund, Christian Winther, et al. "Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3." HemaSphere vol. 5,1 (2021): e510. doi: https://doi.org/10.1097/HS9.0000000000000510
Eskelund CW, Dimopoulos K, Kolstad A, Glimelius I, Räty R, Gjerdrum LMR, Sonnevi K, Josefsson P, Nilsson-Ehle H, Bentzen HHN, Fagerli UM, Kuittinen O, Haaber J, Niemann CU, Pedersen LB, Larsen MT, Geisler CH, Hutchings M, Jerkeman M, Grønbæk K. Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3. Hemasphere. 2020 Dec 21;5(1):e510. doi: 10.1097/HS9.0000000000000510. eCollection 2021 Jan. PMID: 33364550; PMCID: PMC7755521.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries